+

WO2002049624A3 - Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists - Google Patents

Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists Download PDF

Info

Publication number
WO2002049624A3
WO2002049624A3 PCT/EP2001/014568 EP0114568W WO0249624A3 WO 2002049624 A3 WO2002049624 A3 WO 2002049624A3 EP 0114568 W EP0114568 W EP 0114568W WO 0249624 A3 WO0249624 A3 WO 0249624A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
compositions based
dopamine agonists
novel pharmaceutical
anticholinergic agents
Prior art date
Application number
PCT/EP2001/014568
Other languages
German (de)
French (fr)
Other versions
WO2002049624A2 (en
Inventor
Michel Pairet
Michael Paul Pieper
Christopher John Montagu Meade
Original Assignee
Boehringer Ingelheim Pharma
Michel Pairet
Michael Paul Pieper
Christopher John Montagu Meade
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Michel Pairet, Michael Paul Pieper, Christopher John Montagu Meade filed Critical Boehringer Ingelheim Pharma
Priority to AU2002235767A priority Critical patent/AU2002235767A1/en
Priority to EP01985868A priority patent/EP1345626A2/en
Priority to JP2002550966A priority patent/JP2004516264A/en
Priority to MXPA03005585A priority patent/MXPA03005585A/en
Priority to CA002430592A priority patent/CA2430592C/en
Publication of WO2002049624A2 publication Critical patent/WO2002049624A2/en
Publication of WO2002049624A3 publication Critical patent/WO2002049624A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists, a method for the production of said compositions and the use of the same for the treatment of respiratory tract diseases.
PCT/EP2001/014568 2000-12-20 2001-12-12 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists WO2002049624A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002235767A AU2002235767A1 (en) 2000-12-20 2001-12-12 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
EP01985868A EP1345626A2 (en) 2000-12-20 2001-12-12 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
JP2002550966A JP2004516264A (en) 2000-12-20 2001-12-12 Novel pharmaceutical compositions based on anticholinergics and dopamine agonists
MXPA03005585A MXPA03005585A (en) 2000-12-20 2001-12-12 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists.
CA002430592A CA2430592C (en) 2000-12-20 2001-12-12 New pharmaceutical compositions based on anticholinergics and dopamine agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10063957.7 2000-12-20
DE10063957A DE10063957A1 (en) 2000-12-20 2000-12-20 New drug compositions based on anticholinergics and dopamine agonists

Publications (2)

Publication Number Publication Date
WO2002049624A2 WO2002049624A2 (en) 2002-06-27
WO2002049624A3 true WO2002049624A3 (en) 2002-09-19

Family

ID=7668263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014568 WO2002049624A2 (en) 2000-12-20 2001-12-12 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists

Country Status (7)

Country Link
EP (1) EP1345626A2 (en)
JP (1) JP2004516264A (en)
AU (1) AU2002235767A1 (en)
CA (1) CA2430592C (en)
DE (1) DE10063957A1 (en)
MX (1) MXPA03005585A (en)
WO (1) WO2002049624A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1674887A (en) * 2002-08-14 2005-09-28 贝林格尔英格海姆法玛两合公司 Aerosol formulation for inhalation comprising an anticholinergic

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145852A (en) * 1989-07-11 1992-09-08 Ronald Virag Vaso-active medicament to treat impotence
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones
US5712265A (en) * 1988-05-10 1998-01-27 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinin receptor antagonists for treatment of glucose metabolism disorders
DE19835346A1 (en) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Two-part capsule for pharmaceutical preparations for powder inhalers
US6045778A (en) * 1992-12-09 2000-04-04 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
WO2001012167A2 (en) * 1999-08-18 2001-02-22 Astrazeneca Uk Limited Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712265A (en) * 1988-05-10 1998-01-27 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinin receptor antagonists for treatment of glucose metabolism disorders
US5145852A (en) * 1989-07-11 1992-09-08 Ronald Virag Vaso-active medicament to treat impotence
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones
US6045778A (en) * 1992-12-09 2000-04-04 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
DE19835346A1 (en) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Two-part capsule for pharmaceutical preparations for powder inhalers
WO2001012167A2 (en) * 1999-08-18 2001-02-22 Astrazeneca Uk Limited Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"VIOZAN TM", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 25, no. 2, 2000, pages 165 - 169, XP000911169, ISSN: 0377-8282 *
BARNES P J: "Chronic obstructive pulmonary disease: new opportunities for drug development", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 19, no. 10, October 1998 (1998-10-01), pages 415 - 423, XP004156947, ISSN: 0165-6147 *
CHAN T Y: "Low-dose dopamine in severe right heart failure and chronic obstructive pulmonary disease.", THE ANNALS OF PHARMACOTHERAPY. UNITED STATES MAY 1995, vol. 29, no. 5, May 1995 (1995-05-01), pages 493 - 496, XP001085014, ISSN: 1060-0280 *
FEIGENSON J S ET AL: "PIRIBEDIL: ITS SYNERGISTIC EFFECT IN MULTIDRUG REGIMENS FOR PARKINSONISM", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 26, no. 5, 1 May 1976 (1976-05-01), pages 430 - 433, XP002051862, ISSN: 0028-3878 *
PAVIA D ET AL: "PRELIMINARY DATA FROM PHASE II STUDIES WITH RESPIMAT, A PROPELLANT-FREE SOFT MIST INHALER", JOURNAL OF AEROSOL MEDICINE, MARY ANN LIEBERT, INC., NEW YORK, US, vol. SUPPL. 1, no. 12, September 1999 (1999-09-01), pages S33 - S39, XP001078739, ISSN: 0894-2684 *

Also Published As

Publication number Publication date
MXPA03005585A (en) 2004-05-05
DE10063957A1 (en) 2002-06-27
WO2002049624A2 (en) 2002-06-27
EP1345626A2 (en) 2003-09-24
JP2004516264A (en) 2004-06-03
AU2002235767A1 (en) 2002-07-01
CA2430592C (en) 2008-02-26
CA2430592A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
YU35503A (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
MXPA03011515A (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents.
YU71901A (en) NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND beta-MIMETICS
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
MXPA03005340A (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides.
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2004047838A3 (en) Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
HK1128679A1 (en) 1,2-diphenylethene derivatives for treatment of immune diseases 12-
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
MXPA03010761A (en) Pharmaceutical combinations.
RS98704A (en) New pharmaceutical compositions containing flibanserin polymorpha
MXPA03007635A (en) P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same.
WO2001058875A3 (en) Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
WO2007144699A3 (en) Process for the preparation of alfuzosin
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2004043982A3 (en) Novel ampiphilic derivatives of alpha-c-phenyl n-tert-butyl nitrone
WO2002074034A3 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
WO2003024996A3 (en) Antibacterial macrocycles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001985868

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2430592

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002550966

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005585

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001985868

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载